These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 19659611)

  • 1. Simultaneous suppression of MITF and BRAF V600E enhanced inhibition of melanoma cell proliferation.
    Kido K; Sumimoto H; Asada S; Okada SM; Yaguchi T; Kawamura N; Miyagishi M; Saida T; Kawakami Y
    Cancer Sci; 2009 Oct; 100(10):1863-9. PubMed ID: 19659611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
    Kundu A; Quirit JG; Khouri MG; Firestone GL
    Mol Carcinog; 2017 Jan; 56(1):49-61. PubMed ID: 26878440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF.
    Wellbrock C; Rana S; Paterson H; Pickersgill H; Brummelkamp T; Marais R
    PLoS One; 2008 Jul; 3(7):e2734. PubMed ID: 18628967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression.
    Bonet C; Luciani F; Ottavi JF; Leclerc J; Jouenne FM; Boncompagni M; Bille K; Hofman V; Bossis G; Marco de Donatis G; Strub T; Cheli Y; Ohanna M; Luciano F; Marchetti S; Rocchi S; Birling MC; Avril MF; Poulalhon N; Luc T; Hofman P; Lacour JP; Davidson I; Bressac-de Paillerets B; Ballotti R; Marine JC; Bertolotto C
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological attenuation of melanoma by tryptanthrin pertains to the suppression of MITF-M through MEK/ERK signaling axis.
    Shabna A; Antony J; Vijayakurup V; Saikia M; Liju VB; Retnakumari AP; Amrutha NA; Alex VV; Swetha M; Aiswarya SU; Jannet S; Unni US; Sundaram S; Sherin DR; Anto NP; Bava SV; Chittalakkottu S; Ran S; Anto RJ
    Cell Mol Life Sci; 2022 Aug; 79(9):478. PubMed ID: 35948813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A genomic screen identifies TYRO3 as a MITF regulator in melanoma.
    Zhu S; Wurdak H; Wang Y; Galkin A; Tao H; Li J; Lyssiotis CA; Yan F; Tu BP; Miraglia L; Walker J; Sun F; Orth A; Schultz PG; Wu X
    Proc Natl Acad Sci U S A; 2009 Oct; 106(40):17025-30. PubMed ID: 19805117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TYRP1 mRNA level is stable and MITF-M-independent in drug-naïve, vemurafenib- and trametinib-resistant BRAF
    Hartman ML; Czyz M
    Arch Dermatol Res; 2020 Jul; 312(5):385-392. PubMed ID: 31624899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF
    Smith MP; Rana S; Ferguson J; Rowling EJ; Flaherty KT; Wargo JA; Marais R; Wellbrock C
    Pigment Cell Melanoma Res; 2019 Mar; 32(2):280-291. PubMed ID: 30277012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells.
    Pathria G; Garg B; Borgdorff V; Garg K; Wagner C; Superti-Furga G; Wagner SN
    Cell Death Dis; 2016 Mar; 7(3):e2135. PubMed ID: 26962685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A conditional zebrafish MITF mutation reveals MITF levels are critical for melanoma promotion vs. regression in vivo.
    Lister JA; Capper A; Zeng Z; Mathers ME; Richardson J; Paranthaman K; Jackson IJ; Elizabeth Patton E
    J Invest Dermatol; 2014 Jan; 134(1):133-140. PubMed ID: 23831555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
    Müller J; Krijgsman O; Tsoi J; Robert L; Hugo W; Song C; Kong X; Possik PA; Cornelissen-Steijger PD; Geukes Foppen MH; Kemper K; Goding CR; McDermott U; Blank C; Haanen J; Graeber TG; Ribas A; Lo RS; Peeper DS
    Nat Commun; 2014 Dec; 5():5712. PubMed ID: 25502142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation.
    Wellbrock C; Marais R
    J Cell Biol; 2005 Aug; 170(5):703-8. PubMed ID: 16129781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-M(high) melanoma cell populations.
    Hartman ML; Talar B; Sztiller-Sikorska M; Nejc D; Czyz M
    Oncotarget; 2016 Feb; 7(8):9026-40. PubMed ID: 26824319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-depth genomic data analyses revealed complex transcriptional and epigenetic dysregulations of BRAFV600E in melanoma.
    Guo X; Xu Y; Zhao Z
    Mol Cancer; 2015 Mar; 14():60. PubMed ID: 25890285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A common intronic variant of PARP1 confers melanoma risk and mediates melanocyte growth via regulation of MITF.
    Choi J; Xu M; Makowski MM; Zhang T; Law MH; Kovacs MA; Granzhan A; Kim WJ; Parikh H; Gartside M; Trent JM; Teulade-Fichou MP; Iles MM; Newton-Bishop JA; Bishop DT; MacGregor S; Hayward NK; Vermeulen M; Brown KM
    Nat Genet; 2017 Sep; 49(9):1326-1335. PubMed ID: 28759004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MITF-independent pro-survival role of BRG1-containing SWI/SNF complex in melanoma cells.
    Ondrušová L; Vachtenheim J; Réda J; Záková P; Benková K
    PLoS One; 2013; 8(1):e54110. PubMed ID: 23349796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF/MAPK and GSK3 signaling converges to control MITF nuclear export.
    Ngeow KC; Friedrichsen HJ; Li L; Zeng Z; Andrews S; Volpon L; Brunsdon H; Berridge G; Picaud S; Fischer R; Lisle R; Knapp S; Filippakopoulos P; Knowles H; Steingrímsson E; Borden KLB; Patton EE; Goding CR
    Proc Natl Acad Sci U S A; 2018 Sep; 115(37):E8668-E8677. PubMed ID: 30150413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
    Konieczkowski DJ; Johannessen CM; Abudayyeh O; Kim JW; Cooper ZA; Piris A; Frederick DT; Barzily-Rokni M; Straussman R; Haq R; Fisher DE; Mesirov JP; Hahn WC; Flaherty KT; Wargo JA; Tamayo P; Garraway LA
    Cancer Discov; 2014 Jul; 4(7):816-27. PubMed ID: 24771846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition.
    Haq R; Yokoyama S; Hawryluk EB; Jönsson GB; Frederick DT; McHenry K; Porter D; Tran TN; Love KT; Langer R; Anderson DG; Garraway LA; Duncan LM; Morton DL; Hoon DS; Wargo JA; Song JS; Fisher DE
    Proc Natl Acad Sci U S A; 2013 Mar; 110(11):4321-6. PubMed ID: 23447565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF.
    Haq R; Shoag J; Andreu-Perez P; Yokoyama S; Edelman H; Rowe GC; Frederick DT; Hurley AD; Nellore A; Kung AL; Wargo JA; Song JS; Fisher DE; Arany Z; Widlund HR
    Cancer Cell; 2013 Mar; 23(3):302-15. PubMed ID: 23477830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.